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Abstract objectives Human T-lymphotropic virus (HTLV)-1 causes T-cell leukaemia and myelopathy.
Together with HTLV-2, it is endemic in some African nations. Seroprevalence data from Malawi are
scarce, with no reports on associated disease incidence. HTLV seroprevalence and type were tested in
418 healthy mothers from Malawi. In addition, we tested the sera of 534 children to investigate
mother-to-child transmission. To provide context, we conducted a systematic review and meta-
analysis of HTLV seroprevalence in African women and children.
methods Stored samples from a previous childhood cancer and BBV study were analysed. ELISA
was used for HTLV screening followed by immunoblot for confirmation and typing. Standard
methods were used for the systematic review.
results HTLV seroprevalence was 2.6% (11/418) in mothers and 2.2% (12/534) in children. Three
mothers carried HTLV-1 alone, seven had HTLV-2 and one was dually infected. Three children
carried HTLV-1 alone, seven had HTLV-2 and two were dually infected. Only two corresponding
mothers of the 12 HTLV-positive children were HTLV positive. The systematic review included 66
studies of women and 13 of children conducted in 25 African countries. Seroprevalence of HTLV-1
varied from 0 to 17% and of HTLV-2 from 0 to 4%.
conclusions In contrast to findings from other studies in Africa, the seroprevalence of HTLV-2
was higher than that of HTLV-1 in Malawi and one of the highest for the African region. The lack
of mother–child concordance suggests alternative sources of infection among children. Our data and
analyses contribute to HTLV prevalence mapping in Africa.
keywords Africa, Human T-lymphotropic virus, Malawi, prevalence, seroprevalence, mother-to-child
transmission, MTCT, HTLV-1, HTLV-2, systematic review, meta-analysis, healthy women
Introduction
HTLV-1 is the causative agent of aggressive adult T-cell
leukaemia/lymphoma (ATLL) and the progressive,
chronic, disabling HTLV-1-associated myelopathy/tropi-
cal spastic paraparesis (HAM/TSP) as well as other
inflammatory conditions such as infective dermatitis and
uveitis [1]. Surveillance data for prevalence of these two
conditions are scarce and virtually unavailable for large
areas such as China, India and many African countries.
Even fewer data are available on prevalence and
pathogenicity of HTLV-2, which is known to be endemic
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in African Pygmies [2] and Native Americans [3]. In the
United States, HTLV-2 is more common than HTLV-1
and is associated with female sex, older age, Asian, His-
panic and African ethnicity, low level of education, a his-
tory of injecting drug use in the 1960s/1970s (a result of
birth cohort effects) and residence in western and south-
western USA, where HTLV-2 clusters are found [4].
There are case reports describing associations between
HTLV-2 and a small increased risk of bacterial infec-
tions, particularly of the chest and bladder [5], increased
cancer risk [6] and rare reports of HAM/TSP [7].
HTLV-1, an oncogenic human RNA retrovirus, was
discovered 35 years ago [8], followed by the identifica-
tion of HTLV-2, HTLV-3 and HTLV-4 [9–11]. These
human viruses have arisen through inter-species transmis-
sion of simian T-lymphotropic viruses (STLV) [12].
HTLV-1 is found in endemic clusters and an estimated
10–20 million individuals, worldwide, are infected [2,
13]. Virus is transmitted from human-to-human through
infected lymphocytes and may be acquired through
mother-to-child transmission (MTCT): at birth and more
commonly through breastfeeding, sexual intercourse,
blood transfusions, organ transplantations and contami-
nated needle reuse.
The African continent has a population over 1 billion
and represents the largest endemic area for HTLV infec-
tion but with many data gaps. HTLV seroprevalence has
been reported only once in Malawi, at 2.5%, when 159
blood donor sera were screened by ELISA, without typ-
ing or confirmatory testing [14]. HTLV associated dis-
eases have not been reported in Malawi, which may be
due to limited diagnosis, lack of surveillance and poor
survival.
This study investigated the prevalence of anti-HTLV-1
and HTLV-2 antibodies in stored sera from a previous
childhood cancer study. We had access to the sera of 534
children diagnosed with cancer in Blantyre, Malawi and
418 paired healthy mothers. ELISA positive tests were
confirmed and typed by immunoblotting. In addition, we
applied context to our results by conducting a systematic
review and meta-analysis of published HTLV seropreva-
lence data of African women and children.
Methodology
Study population
Anonymised stored serum samples from Malawian chil-
dren (n = 534) and, where available, from their biologi-
cal mothers (n = 418), were tested. Samples had been
originally collected as part of a childhood malignancy
and blood-borne virus (BBV) study at the Queen
Elizabeth Central Hospital in Blantyre, Malawi between
2006 and 2010 [15]. Their mothers were the children’s
healthy controls as part of this original study. Ethical
approval for the study was obtained from the Oxford
Tropical Research Ethics Committee and the Malawian
College of Medicine Research and Ethics Committee. Writ-
ten informed consent was obtained from mothers and the
guardians of the children. Details of the original study are
published elsewhere [15]. Demographic data were not
available for all children (minimum n = 174, maximum
n = 276) or mothers (minimum n = 140, maximum
n = 209), and data were not available for all data points.
Results are, therefore, presented as % of data available.
Screening, confirmation and typing of HTLV
Replicating clinical diagnostic algorithms, the study proto-
col required that all ELISA reactive samples underwent
immunoblot (IB) confirmatory testing. Only indeterminate
IBs were tested further with polymerase chain reaction
(PCR), where whole blood was available. All sera were
screened in duplicate by ELISA (MP Diagnostics HTLV-1/
2 ELISA v4, antibodies against gp46-I, gp46-II, GD21) fol-
lowing the manufacturers’ instructions (MP Biomedicals,
Cambridge, Cambridgeshire, UK). ELISA reactive or bor-
derline reactive sera were tested and typed as HTLV-1,
HTLV-2, HTLV-1 and HTLV-2, negative and indetermi-
nate using an FDA approved, confirmatory, qualitative
enzyme immunoblot assay (IB), (MP Diagnostics HTLV
blot v2.4), which were interpreted using the HTLV Euro-
pean Research Network guidelines [16, 17]. Both assays
included HTLV-positive serum controls provided by the
manufacturer. Where frozen whole blood was available,
samples typed as indeterminate were further tested for the
presence of HTLV DNA (n = 18). DNA was isolated from
frozen whole blood of serologically indeterminate samples
and its integrity was confirmed by optimised PCR amplifi-
cation of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) using commercially available primers. Samples
were tested for the presence of HTLV-1 DNA by PCR as
previously described [18].
Systematic review
PRISMA guidelines for systematic reviews and meta-ana-
lyses were adhered to during protocol design and analy-
ses. The NCBI PubMed database was searched using the
search terms ‘HTLV’, ‘human T-lymphotropic virus’,
‘mother’, ‘child’, ‘transmission’ plus each respective Afri-
can nation to 31 December 2014.
The inclusion criteria were cross-sectional seropreva-
lence studies; healthy women (to match our cohort,
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including blood donors, ante-natal clinic attendees,
healthy volunteers); sex workers; children; living in
Africa; opt-in, opt-out or anonymous un-linked (blood
tests/other body fluid); approved by ethics; screened for
HTLV; and confirmed with a confirmatory test (CT), and
studies with zero seroprevalence by ELISA were included
(Figure 1). The exclusion criteria were case reports; co-
infection studies in an already known infected popula-
tion; ill patients (hospitalised, patients with underlying
diagnosis); no CT; men; seroprevalence by gender unspec-
ified; patient self-reporting; and not in English language
(Figure 1).
Applying the above criteria at stage 1 all potential
papers’ titles and abstracts were screened, and at stage 2
duplicates and papers not fitting all criteria were removed
(Figure 1). Data were collected in Excel: location, year of
publication, authors, study title, study characteristics,
cohort gender, sample size, seroprevalence using ELISA,
seroprevalence using confirmatory test and PCR con-
firmed. All citations on included papers were checked for
any additional studies with one additional study identified
not in the original PubMed searches (Figure 1). Data were
screened and extracted by JF and checked by FM and
MB. Any discordance was resolved through discussion.
PubMed search term: HTLV & each African nation
(N = 766)
HTLV prevalence by
HTLV prevalence by
African nation in healthy
African nation in healthy
humans + study identified
post PubMed search
(N = 210)
Removed: duplicates,
prevalence not reported,
in vitro, animal, non-
English language, ill or
affected humans
(N = 556)
women/children using
ELISA
(N = 153)
Removed: male
prevalence only,
women/children data
could not be extracted,
non-ELISA screening
(N = 57)
Confirmed HTLV
prevalence or ELISA  0%
prevalence by African
nation in healthy
women/children
(N = 68)
Removed: all non-
confirmed ELISA
prevalence reports
[Left in: studies that had
ELISA negative cohorts
where confirmation not
required]
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ed Figure 1 Flow chart of all manuscripts
screened for prevalence of HTLV in
healthy women and children living in
Africa. Ten publications had data for
both women and children.
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Meta-analysis
The confidence intervals for individual studies were calcu-
lated by the exact binomial method and the combined esti-
mate by random effects meta-analysis using the logistic
transformation. Where there were no observed HTLV
cases, giving zero seroprevalence, 0.5 was added to fre-
quencies for the meta-analysis. There were much variabil-
ity between studies; therefore, they all received similar
weights in random effects meta-analysis. Forest plots were
created from the results of the meta-analysis: squares rep-
resent the prevalence’s reported for the individual studies,
square areas being proportional to the weight the study
received in the meta-analysis. Horizontal lines show the
95% confidence intervals for the prevalence. The diamond
shapes represent the combined estimates for each region,
the deepest point being the estimated combined prevalence
and the width of the diamond representing the 95% confi-
dence interval. The confidence intervals were calculated on
the log odds scale and transformed back to the proportion
scale, and so they are not symmetrical. The data presented
here were incorporated into the final analyses to give
regional HTLV seroprevalence estimates.
Results
Demographics
Several data points were collected as part of the original
publication [15], and we summarised it to have an over-
all picture of the cohorts’ socio-economical and health
status; universal data were not available. 40% of children
were female; mean age was 7.3 years (range 0.2–16). A
total of 48% of children had Burkitt’s, 12% neuroblas-
toma, none had ATLL. Only 12% of the mothers of the
children had an illness during pregnancy, only 5.6%
needed an intervention during delivery (caesarean section,
stitches or assistance), 68% were delivered at home, only
4% were preterm deliveries. After birth, 98% were
breastfed, 34% ≥2 years, 11% had blood transfusions,
51% had ever received an injection and 18% had a hos-
pital admission before sampling; 81% had malaria in the
past and 9% were HIV positive.
A total of 76% of mothers were married, 48% had >5
pregnancies, 45% had received injectable contraception,
36% reported to have had >1 partner, 9% reported hav-
ing their first sexual intercourse during primary schooling
and 34% during secondary school, 99% reported never
having engaged in sex work, 94% never used condoms
and 26% were HIV positive. A total of 81% of house-
holds had no electricity and 79% of children had to share
plates with family members.
Screening for HTLV prevalence in Malawian women and
children
Twenty-seven mothers’ sera samples were repeatedly
ELISA reactive and one was borderline reactive. Ten of
28 were HTLV-positive by IB of which two were
HTLV-1 positive, seven HTLV-2 and one was positive
for both anti-HTLV-1 and anti-HTLV-2 antibodies
(Table 1). HTLV-1-specific DNA was amplified by PCR
from whole blood from 1/18 IB indeterminate partici-
pants; no HTLV-1 or HTLV-2-specific DNA could be
amplified from the remaining 17 indeterminate samples.
Therefore, the final HTLV prevalence in 418 healthy
women was 2.6%: three mothers were typed HTLV-1
(0.7%) and seven HTLV-2 (1.7%) with one (0.2%)
mother being dually infected (Table 1).
Of 534 children, 82 sera were ELISA reactive and 12
by IB; three were typed HTLV-1, seven HTLV-2 and two
HTLV-1 and HTLV-2 (Table 1). Only two children of
HTLV-positive mothers were also confirmed to be HTLV
positive: the child of the HTLV-1 and HTLV-2 mother
was HTLV-2 positive and the child of a mother with
HTLV-1 was HTLV-1 and HLTV-2 positive. The moth-
ers of the remaining 10 HTLV-positive children were all
HTLV seronegative. Whole blood was not available for
any child.
In summary, the HTLV seroprevalence in children was
2.2%: 0.6% for HTLV-1, 1.3% for HTLV-2 and 0.4%
for HTLV-1/2 infection (Table 1).
Demographic data were not available for all the
HTLV-positive cases. However, where data were avail-
able, none of the HTLV-positive children or mothers
were HIV coinfected. Otherwise they resembled the rest
of the HTLV-negative cohort. Mothers were married,
had never used condoms, had never engaged in sex work,
had > 5 pregnancies and only one had received injectable
contraception. Children’s mean age was 8 years (range:
2.5–13.4 years), had been born vaginally, had not been
born prematurely, had been breastfed for >2 years. Only
one child had received injections in the past but none had
had a blood transfusion and only three had a history of
malaria.
Table 1 HTLV seroprevalence in Malawi: screening of 418
mothers and 534 children and results of confirmatory testing of
ELISA-positive samples
N
HTLV-1
(%)
HTLV-2
(%)
HTLV-1
and
HTLV-2 (%) Total (%)
Mothers 418 3 (0.7) 7 (1.7) 1 (0.2) 11 (2.6)
Children 534 3 (0.6) 7 (1.3) 2 (0.4) 12 (2.2)
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Systematic review and meta-analysis of HTLV prevalence
in Africa
At stage 1, 766 PubMed publications on HTLV in Afri-
can countries were identified. At stage 2, all publications
that met the outlined inclusion/exclusion criteria were
collected. Specific effort was made to extract data on
women and children only from the manuscripts. Data
were available for 24 countries for women and eight for
children and were published between 1988 and 2014 for
women and between 1988 and 1999 for children. Thirty-
four studies had data for cohorts of healthy volunteers,
three for blood donors, twenty-two for antenatal care
(ANC) attendees and fifteen for sex workers. Mean sam-
ple size for women was 609 (range 26–2070) and 562
for children (range 46–1323). Some manuscripts gave
data on multiple subgroups of study population therefore
additional data sets were created. In the first instance,
analysis was conducted on 74 data sets for women (Table
3, Figure 2) and 13 for children (Table 4, Figure 3) from
a total of 68 publications, three of which contained data
for children only (Figure 1, Table 2). Malawi findings
were included in final analyses (Tables 3/4, Figures 2/3).
We analysed data by country and region (North, West
and Central, East and Southern Africa) but deliberately
refrained from calculating a prevalence estimate for the
African continent (Table 3, Figure 2). For women, the
highest seroprevalence of HTLV was reported in West
and Central Africa (3.2%, 95%CI 2.6-4.0), which was
also the source of the most studies (54/74 data sets, 13
countries). Limited data were available for children but
West and Central Africa was again the most commonly
studied region (10 of 13 data sets, 5 countries) with an
estimated HTLV seroprevalence of 2.0% (95%CI 1.2-
3.4) (Table 4, Figure 3). Both for women and children,
the most commonly reported subtype was HTLV-1.
HTLV-1 and HTLV-2 dual infections in healthy women
and children were only reported in Nigeria, at 2.2% and
0.2%, respectively, and in sex workers at 1.67%
(Table 2).
Assuming that sex workers may have an unusually high
exposure risk we compared them to other women using
logistic regression with robust standard errors allowing
for the clustering in studies and adjusting for region. The
odds ratio of HTLV for sex workers compared to all
other women was 1.34 (95% CI 0.80–2.23, P = 0.3).
Therefore, although they had a slightly higher risk of
being positive for HTLV, this may have been due to
chance variation; therefore, sex workers were not
excluded from the analysis.
HTLV is more prevalent in sexually active and older
women [2]. Analysis of HTLV by age stratification could
not be conducted as age was not available on all the
mothers in our study; however, they were all sexually
active and of reproductive age.
In light of the HTLV-2 seroprevalence in our Malawi
study, we were interested to know the seroprevalence of
HTLV-2 in Africa. HTLV-2 had been observed in 11 of
74 data sets for women with stark regional variability:
Eritrea 2.1%, Cameroon 0.3% and 0.8%, Gabon 1.1
and 0.1%, Ghana 0.1%, Guinea-Bissau 0.1% (on two
occasions), Nigeria 1.1% and 3.9% (Table 2). HTLV-2
was concentrated in women of Pygmy origin. Two of 13
studies reported HTLV-2 in children: Nigeria 0.5% and
Gabon 0.3% (Table 2).
Focusing on countries neighbouring Malawi, HTLV-2
was not observed in four studies originating from
Mozambique (combined total sample size: 1564) [19–22]
nor in the only Zambian study [23]; publications from
Tanzania did not report confirmatory testing and were
excluded from the meta-analysis. Our observation of
HTLV-2 at 1.7% in women and 1.3% in children was
high in comparison with the rest of Africa as well as
neighbouring countries, but similar to Nigeria and Eri-
trea.
Discussion
To our knowledge, this is the first report on the sero-
prevalence and type of HTLV in Malawi combining
screening with robust confirmatory testing. We had
access to stored sera of children with childhood cancers
and their mothers as their controls who had taken part in
a previous study [15]. HTLV seroprevalence was 2.6% in
mothers and 2.2% in children. HTLV-2 was seen more
commonly at 1.7% and 1.3% for mothers and children
compared to 0.7% and 0.6% for HTLV-1, respectively.
None of the HTLV-positive cases were hepatitis C [24]
or HIV positive. High levels of HTLV intermediate
screening results are commonly seen in African sera [25];
only one of the 18 tested indeterminate samples could be
resolved by DNA testing. Ten of 12 HTLV-positive chil-
dren had HTLV-negative mothers.
In this retrospective study, the mothers were of child-
bearing age with known multiple pregnancies but we
can only make assumptions about their HTLV acquisi-
tion. They could have acquired these viruses through:
MTCT from their own mothers; unprotected sex; con-
tact with non-human primates (bites/hunting/butchering,
pets), use of unsterile instrumentation (female genital
mutilation [FGM], tattooing/piercing) or contaminated
needles; unscreened blood products or other means not
yet characterised. Bush-meat hunting, heroin trafficking
and FGM are prevalent in Malawi although not
316 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Table 2 Systematic review of all included manuscripts reporting African HTLV prevalence in healthy women and children
Reference Year Nation Region Cohort Size
Prevalence %
HTLV-1 HTLV-2 Dual Total
Larouze et al. [42] 1985 Algeria North SW 140 0.00 0.00 0.00 0.00
Constantine et al. [43] 1991 Egypt North SW 158 0.00 0.00 0.00 0.00
Larouze et al. [42] 1985 Tunisia North HV 442 0.00 0.00 0.00 0.00
Fox et al. [44] 1988 Djibouti East SW 327 1.22 0.00 0.00 1.22
Constantine et al. [45] 1992 Djibouti East ANC 33 6.06 0.00 0.00 6.06
Andersson et al [46] 1999 Eritrea East SW 97 0.00 2.06 0.00 2.06
ANC 113 0.00 0.00 0.00 0.00
Ramos et al. [47] 2011 Ethiopia East ANC 165 0.00 0.00 0.00 0.00
Ramos et al. [48] 2012 Ethiopia East ANC 328 0.00 0.00 0.00 0.00
Scott et al. [49] 1991 Somalia East SW 57 0.00 0.00 0.00 0.00
Bayley et al. [23] 1985 Zambia East HV 132 0.00 0.00 0.00 0.00
Collenberg et al. [50] 2006 Burkina Faso West ANC 492 1.02 0.00 0.00 1.02
Dumas et al. [51] 1991 Benin West HV 1329 1.96 0.00 0.00 1.96
Houinato et al. [52] 1996 Benin West HV 853 1.29 0.00 0.00 1.29
Ndumbe et al. [53] 1992 Cameroon West ANC 170 0.59 0.00 0.00 0.59
Mauclere et al. [54] 1993 Cameroon West SW 391 0.26 0.77 0.00 1.02
Mauclere et al. [55] 1995 Cameroon West SW 332 0.90 0.30 0.00 1.20
Mauclere et al. [56] 1997 Cameroon West HV 1977 1.52 0.00 0.00 1.52
Filippone et al. [33] 2012 Cameroon West HV* 978 2.04 0.00 0.00 2.04
Gessain et al. [28] 1993 CAR West HV 689 0.29 0.00 0.00 0.29
Wiktor et al. [57] 1990 DR Congo West SW 377 3.18 0.00 0.00 3.18
Goubau et al. [58] 1993 DR Congo West HV 1956 2.15 0.00 0.00 2.15
Jeannel et al. [59] 1993 DR Congo West HV 352 0.85 0.00 0.00 0.85
Delaporte et al. [60] 1995 DR Congo West ANC 1160 3.71 0.00 0.00 3.71
SW 1183 7.27 0.00 0.00 7.27
Tuppin et al. [61] 1996 DR Congo West ANC 2070 0.68 0.00 0.00 0.68
Schrijvers et al. [62] 1991 Gabon West HV 651 6.76 0.00 0.00 6.76
Delaporte et al. [63] 1993 Gabon West HV 30 16.67 0.00 0.00 16.67
Delaporte et al. [40] 1993 Gabon West ANC 434 7.14 0.00 0.00 7.14
Le Hesran et al. [64] 1994 Gabon West HV 505 13.07 0.00 0.00 13.07
Bertherat et al. [65] 1998 Gabon West HV 275 7.27 1.09 0.00 8.36
Moynet et al. [66] 2001 Gabon West HV 311 7.90 0.00 0.00 7.90
Etenna et al. [67] 2008 Gabon West ANC 907 2.09 0.11 0.00 2.21
Biggar et al. [68] 1993 Ghana West HV 1242 1.29 0.00 0.00 1.29
Apea-Kubi et al. [69] 2006 Ghana West ANC 294 2.72 0.00 0.00 2.72
Armah et al. [70] 2006 Ghana West ANC 960 2.08 0.10 0.00 2.19
Jeannel et al. [71] 1995 Guinea West HV 718 2.23 0.00 0.00 2.23
Naucler et al. [72] 1992 Guinea-Bissau West ANC 272 3.31 0.00 0.00 3.31
Norrgren et al. [73] 1995 Guinea-Bissau West HV 143 4.90 0.00 0.00 4.90
Andersson et al. [74] 1997 Guinea-Bissau West ANC 1231 2.19 0.08 0.00 2.27
Melbye et al. [75] 1998 Guinea-Bissau West HV 193 12.44 0.00 0.00 12.44
Larsen et al. [76] 2000 Guinea-Bissau West HV 1183 4.73 0.08 0.00 4.82
Holmgren et al. [77] 2002 Guinea-Bissau West HV 1605 5.79 0.00 0.00 5.79
Holmgren et al. [78] 2003 Guinea-Bissau West HV 816 10.17 0.00 0.00 10.17
Ariyoshi et al. [79] 2003 Guinea-Bissau West HV 105 10.48 0.00 0.00 10.48
Norrgren et al. [80] 2008 Guinea-Bissau West HV 1050 3.24 0.00 0.00 3.24
da Silva et al. [81] 2009 Guinea-Bissau West HV 1507 2.92 0.00 0.00 2.90
Ouattara et al. [82] 1989 Ivory Coast West HV 594 2.02 0.00 0.00 2.02
SW 149 2.68 0.00 0.00 2.68
Verdier et al. [83] 1989 Ivory Coast West ANC 513 1.95 0.00 0.00 1.95
SW 390 7.44 0.00 0.00 7.44
Dada et al. [84] 1993 Nigeria West SW 885 2.82 0.00 0.00 2.82
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sufficiently surveyed [26]. To our knowledge, no publica-
tions examining IVDU in Malawi are available, but a sys-
tematic review of data on IVDU in African populations
showed that IVDU was more prevalent in adult males (66–
94% of IVDU use) and almost exclusively seen in female
sex workers [26]. In our cohort, none of the HTLV-posi-
tive mothers reported sex work or drug usage or a partner
who had engaged in IVDU. The Malawian blood transfu-
sion service (MBTS) tests blood donations for HIV, HBV,
HCV, syphilis and malaria but not for HTLV (personal
communication with Malawian blood transfusion ser-
vices). Prior to the establishment of the MBTS, one study
assessed the safety of blood donors in Malawi in 2001
[14]. Among 159 blood donations, the prevalence of HIV-
1 infection was 10.7%, 8.1% for HBV carriage, 6.8% for
anti-HCV and 2.5% for anti-HTLV-1.
The lack of concordance between mothers and their
children remains unexplained; it might be an indication
of horizontal transmission or the possibility that the child
had been breastfed by someone other than their mother.
The origin and route of transmission of the unusually
high HTLV-2 seroprevalence found in our study partici-
pants remains unknown and prospective study would
allow verification and identification of infection source.
Table 2 (Continued)
Reference Year Nation Region Cohort Size
Prevalence %
HTLV-1 HTLV-2 Dual Total
Olaleye et al. [85] 1994 Nigeria West SW 60 3.33 3.33 1.67 8.33
Olaleye et al. [86] 1995 Nigeria West ANC 364 5.50 3.85 2.20 11.54
Olaleye et al. [39] 1999 Nigeria West HV 460 4.35 1.09 0.00 5.43
Eltom et al. [87] 2002 Nigeria West SW 863 3.24 0.00 0.00 3.24
Durojaiye et al. [88] 2014 Nigeria West HV 26 0.00 0.00 0.00 0.00
Okoye et al. [89] 2014 Nigeria West ANC 200 0.50 0.00 0.00 0.50
Larouze et al. [42] 1985 Senegal West HV 237 0.00 0.00 0.00 0.00
Diop et al. [90] 2006 Senegal West BD 1315 0.08 0.00 0.00 0.08
ANC 178 1.78 0.00 0.00 1.78
Pepin et al. [91] 1991 The Gambia West SW 354 10.45 0.00 0.00 10.45
Del Mistro et al. [37] 1994 The Gambia West HV 909 1.21 0.00 0.00 1.21
Melo et al. [19] 2000 Mozambique South ANC 132 0.76 0.00 0.00 0.76
Cunha et al. [20] 2007 Mozambique South BD 576 1.22 0.00 0.00 1.22
Gudo et al. [21] 2009 Mozambique South BD 373 0.80 0.00 0.00 0.80
Caterino-de-Araujo et al. [22] 2010 Mozambique South HV 483 2.90 0.00 0.00 2.90
Steele et al. [92] 1994 Namibia South HV* 30 3.33 0.00 0.00 3.33
Botha et al. [93] 1985 South Africa South HV 211 5.21 0.00 0.00 5.21
ANC 911 1.32 0.00 0.00 1.32
Bhigjee et al. [94] 1993 South Africa South HV 527 1.90 0.00 0.00 1.90
Goubau et al. [58] 1993 South Africa South ANC 428 0.23 0.00 0.00 0.23
Bhigjee et al. [95] 1994 South Africa South HV 197 2.54 0.00 0.00 2.54
Taylor et al. [96] 1996 South Africa South ANC 1259 0.56 0.00 0.00 0.56
Andersson et al. [46] 1999 Eritrea East C 161 0.00 0.00 0.00 0.00
Steele et al. [92] 1994 Namibia South C 244 0.82 0.00 0.00 0.82
Taylor et al. [96] 1996 South Africa South C* 1323 0.38 0.00 0.00 0.38
Jeannel et al. [59] 1993 DR Congo West C 715 1.40 0.00 0.00 1.40
Delaporte et al. [97] 1988 Gabon West C 684 2.19 0.00 0.00 2.19
Delaporte et al. [40] 1993 Gabon West C 610 2.79 0.00 0.00 2.79
Le Hesran et al. [64] 1994 Gabon West C 378 3.70 0.00 0.00 3.70
Nyambi et al. [38] 1996 Gabon West C 309 6.80 0.32 0.00 7.12
Verdier et al. [83] 1989 Ivory Coast West C 364 1.37 0.00 0.00 0.00
Williams et al. [98] 1993 Nigeria West C 46 6.52 0.00 0.00 6.52
Olaleye et al. [85] 1994 Nigeria West C 1081 0.74 0.46 0.19 1.39
Olaleye et al. [39] 1999 Nigeria West C 476 1.05 0.00 0.00 1.05
Del Mistro et al. [37] 1994 The Gambia West C 916 0.11 0.00 0.00 0.11
DR Congo, Democratic Republic of Congo; HV, healthy volunteers; HV*, bushwomen; BD, blood donor; ANC, antenatal clinic; SW,
sex worker; C, children, Children*, younger than 72 months of age.
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Our systematic review of HTLV in women and chil-
dren confirmed a distribution of HTLV in large areas
of Africa (West, Central, East and Southern Africa).
HTLV was not detected in healthy women in the three
eligible studies from North Africa (n = 740); this region
seems to have a low HTLV seroprevalence, although
this should be verified with additional larger prevalence
studies.
The prevalence of HTLV-1 in many areas of the world
is poorly mapped and incidence of other subtypes is even
less well known. Africa is thought to be endemic for
HTLV [2], but prevalence data are only partially avail-
able or studies have only be conducted using ELISA with-
out confirmation or typing. East Africa is especially
under surveyed and HTLV untyped. Malawi is known
for its high HIV-1 prevalence (~11%) [27], but HTLV
has only been reported in a single study with a reported
seroprevalence of 2.5% in blood donors [14]. The overall
HTLV seroprevalence in our study was thus very similar
to that found in this previous report. As typing was not
Table 3 Prevalence of HTLV-1 and HTLV-2 in healthy adult women in four geographically defined African regions determined
through meta-analysis of eligible publications defined by the systematic review
Region (sample
number) Countries (sample number)
Without Malawi data With Malawi data
%
seroprevalence 95% CI
%
seroprevalence 95% CI
North (3) Algeria (1), Egypt (1), Tunisia (1) 0.0 0.0–1.1
West and
Central (52)
Benin (2), Burkina Faso (1), Cameroon (5),
Central Africa Republic (1),
DR Congo (6), Gabon (7), Gambia (2),
Ghana (3), Guinea-Bissau (10),
Guinea (1), Ivory Coast (4), Nigeria (7), Senegal (3)
3.2 2.6–4.0
East (8) Djibouti (2), Eritrea (2), Ethiopia (2), Zambia (1)
Somalia (1)
1.0 0.5–2.0
East (9) Djibouti (2), Eritrea (2), Ethiopia (2), Malawi (1),
Zambia (1) Somalia (1)
1.2 0.6–2.3
Southern (11) Mozambique (4), Namibia (1), South Africa (6) 1.6 1.0–2.5
DR Congo, Democratic Republic of Congo.
North
West
Central
East
Southern
Malawi
0 5 10 15
Adult women: HTLV prevalence %
20 25 30 35
and
Figure 2 Forest plot showing prevalence
of HTLV-1 and HTLV-2 among women,
as reported in four regions of Africa,
including data from Malawi. Squares
represent each individual study prevalence
with its area being proportional to the
weight the study received in the meta-
analysis and horizontal lines showing the
95% CI’s. Diamonds represent the
combined estimates for each region with
its width representing the 95% CI.
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performed in the study by Candotti et al., it is possible
that HTLV-2 was present in these blood donors.
In our systematic review only two other African coun-
tries reported high rates of HTLV-2 seroprevalence: Nige-
ria and Eritrea, about 2000 miles apart. HTLV-2 was not
detected in Mozambique or Zambia, neighbouring coun-
tries of Malawi (Table 2). Worldwide, HTLV-2 is ende-
mic in the Americas and associated with IVDU [4], but in
Africa it is endemic in West and Central Africa, as con-
firmed by our systematic review [28–36]. None of the
reviewed studies reported IVDU but mostly unprotected
sex as the risk factor for HTLV acquisition.
Three manuscripts in our systematic review addressed
HTLV MTCT [37–39], two of which also reported
serodiscordance between mothers and their children. In
the first of these studies, Del Mistro et al., identified an
HTLV-1 infected child, from a total of 916 children
screened, whose mother had an indeterminate serological
pattern and a negative HTLV PCR result [37]. Secondly,
Olaleye et al., reported five HTLV-1-positive children of
476 children from a total of 460 mothers in their study;
none of the mothers of the infected children had HTLV
[39]. The other interesting feature of this study was that
none of the 20 HTLV-positive mothers had HTLV-posi-
tive children. Our hypotheses as to how these childhood
infections could have occurred align with those of the
authors of these reports: infection of children with nega-
tive mothers may possibly be a result of repeat blood
transfusions for a variety of conditions, including sickle
cell disease and malaria as well as usage of unsterilised
body scarification instruments [39, 40]. We are aware
that 18% of all the children in our study had historical
hospital admission, in addition approximately 50% were
hospital-born and 11% had received blood transfusions.
However, to our knowledge, none of the HTLV-positive
children in our study had received a blood transfusion.
Breastfeeding is a potential virus transmission route if the
children had been breastfed by an infected wet nurse
other than their HTLV-discordant or HTLV-negative
mother. We had no data on the sexual activity of the
children but only one child was older than 13 years.
Exposure to wildlife and primate bites are additional risk
factors [41].
The strengths of this study were the large total and
matched sample sizes, the combination of highly sensitive
and specific screening and confirmation testing and the
HTLV mapping of Malawi, an under surveyed country.
The study has several limitations. We tested stored sam-
ples and, therefore, were unable to prospectively collect
Table 4 Prevalence of HTLV-1 and HTLV-2 in children in four geographically defined African regions determined through meta-ana-
lysis of eligible publications defined by the systematic review
Region (sample number) Countries (sample number)
Without Malawi data With Malawi data
% seroprevalence 95% CI % seroprevalence 95% CI
North (0)
West and Central (10) DR Congo (1), Gabon (4),
Gambia (1), Ivory Coast (1), Nigeria (3)
2.0 1.2–3.4
East (1)
East (2)
Eritrea (1)
Eritrea (1), Malawi (1)
0.3 0.0–4.7
1.3 0.2–7.1
Southern (2) Namibia (1), South Africa (1) 0.5 0.2–1.0
DR Congo, Democratic Republic of Congo.
West
Central
East
Southern
Malawi
0 10
Children: HTLV prevalence %
20
and
Figure 3 Forest plot showing prevalence of HTLV-1 and
HTLV-2 among children, as reported in three regions of Africa,
including data from Malawi. Squares represent each individual
study prevalence with its area being proportional to the weight
the study received in the meta-analysis and horizontal lines
showing the 95% CI’s. Diamonds represent the combined esti-
mates for each region with its width representing the 95% CI.
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demographic and risk factor data specific to HTLV sero-
prevalence studies. None of the HTLV-positive cases
were HIV positive, which is interesting in itself consider-
ing that both share the same route of transmission. Sam-
ples were also a few years old which might have affected
their reactivity. The cohort of children had cancer and
antibody cross reactivity might have led to false positive
results, although the highly specific confirmatory testing
should negate this risk and HTLV infections were also
found in the healthy women. Additional molecular testing
of seropositive samples would have been ideal but we did
not have access to the required DNA.
In our systematic review, we included data only on
healthy women to best match our cohort of women and
reduce co-infection/co-morbidity bias. There were very
few published reports of childhood HTLV and we
excluded those who were known HIV positive. We
believe data from the 1980s are valuable, although an
overestimation of HTLV prevalence is possible. Further-
more, because African HTLV seroprevalence studies are
limited in their number, we did not exclude any samples
based on study size but calculated regional estimates
rather than national estimates in an attempt to reduce
dependence upon studies with small cohorts. Inherent
bias from small studies and those from the 1980s was
reduced by including only publications that had used
serological confirmatory testing. We used appropriate
study weighting based on cohort size in our analyses and
regional seroprevalence estimates.
In summary, our study highlights that HTLV is preva-
lent in Malawi. However, neither ATLL nor HAM/TSP
has been reported so far. These HTLV-1-associated dis-
eases are difficult to diagnose with high risk of mortality
from ATLL before diagnosis has been made. They are,
therefore, notoriously underreported unless specifically
looked for. In addition, HTLV-2 is not as pathogenic as
HTLV-1 and will be transmitted unknowingly from gen-
eration to generation.
Prospective field studies of HTLV as well as its associ-
ated diseases are needed in Malawi to allow health policy
makers to develop practical and sustainable health poli-
cies with the long-term aim of eradicating HLTV.
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